Nationwide Fund Advisors Raises Holdings in Collegium Pharmaceutical, Inc. (COLL)

Nationwide Fund Advisors grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 27.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,889 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,802 shares during the period. Nationwide Fund Advisors’ holdings in Collegium Pharmaceutical were worth $161,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Credit Suisse AG boosted its stake in shares of Collegium Pharmaceutical by 9.4% during the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after acquiring an additional 1,173 shares in the last quarter. American International Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 27.8% during the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after acquiring an additional 2,163 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Collegium Pharmaceutical by 6.1% during the 1st quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after acquiring an additional 3,775 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Collegium Pharmaceutical by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock worth $1,474,000 after acquiring an additional 4,866 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Collegium Pharmaceutical by 55.0% during the 2nd quarter. Rhumbline Advisers now owns 27,403 shares of the specialty pharmaceutical company’s stock worth $343,000 after acquiring an additional 9,724 shares in the last quarter. 83.96% of the stock is currently owned by institutional investors.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ COLL) opened at $17.14 on Friday. Collegium Pharmaceutical, Inc. has a 52 week low of $7.37 and a 52 week high of $17.73.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The firm had revenue of $11.95 million during the quarter, compared to the consensus estimate of $5.31 million. During the same quarter in the prior year, the company earned ($1.13) EPS. The firm’s revenue for the quarter was up 2814.6% compared to the same quarter last year. equities research analysts forecast that Collegium Pharmaceutical, Inc. will post -2.63 EPS for the current year.

Several analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a research note on Friday. Zacks Investment Research upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Monday, November 13th. Piper Jaffray Companies reiterated a “buy” rating and set a $14.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, September 8th. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $15.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $19.33.

TRADEMARK VIOLATION NOTICE: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.com-unik.info/2017/11/18/nationwide-fund-advisors-raises-holdings-in-collegium-pharmaceutical-inc-coll.html.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the completion of the sale, the chief executive officer now owns 558,987 shares in the company, valued at approximately $8,681,068.11. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 25.76% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

What are top analysts saying about Collegium Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Collegium Pharmaceutical Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit